Colloquy on Neuroblastoma Screening: Is there a future for neuroblastoma mass screening?

Bessho, Fumio

doi:10.1002/(sici)1096-911x(199808)31:2<106::aid-mpo12>3.3.co;2-a

Cited by 1 publication

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The observed association between trends in incidence and mortality and the mass screening permeation process might have been somewhat obscured due to dilution with individuals who were already too old for screening at the time the programme started. However, as already discussed by other investigators,3, 8, 9, 24, 35, 36 there is little evidence that the current screening programme substantially reduces mortality from this childhood tumour. Evaluation of a screening programme that has been offered as a service without prior experimental population‐based evaluation could be possible4 by a nonexperimental method, as applied for cervical cancer 37.…”

Section: Discussionmentioning

confidence: 85%

Neuroblastoma trends in Osaka, Japan, and Great Britain 1970–1994, in relation to screening

Honjo

Doran

Stiller

et al. 2002

Intl Journal of Cancer

View full text Add to dashboard Cite

Japan pioneered and has maintained a nationwide mass screening programme for neuroblastoma since 1985 without prior evaluation among a target population. Convincing population-based evaluation of the ongoing programme has also been very limited because a population-based registry for childhood cancer has not been in operation. This report describes trends in incidence of and mortality from neuroblastoma in Osaka Prefecture, Japan, using Great Britain as an external control, between 1970 and 1994. Incidence and mortality rates were comparable between the 2 areas before the beginning of screening in Osaka. However, incidence rates were markedly increased in Osaka, especially among children younger than 1 year, from 25.9 per million children during 1970 -1979 to 240.2 during 1991-1994, while age-standardized incidence rates for metastatic tumours among children aged 1 year or above did not decrease after introduction of the programme. Age-standardized mortality rates per million were unchanged at 3.

show abstract